The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells
Open accessAbstract
The histone demethylase LSD1 (KDM1A) demethylates mono- and di-methylated (Me2) lysine (K) 4 on histone H3. High LSD1 expression blocks differentiation and confers a poor prognosis in acute myeloid leukemia (AML). Here, treatment with the novel LSD1 antagonist SP2509 attenuated the binding of LSD1 with the corepressor CoREST, increased the permissive H3K4Me3 mark on the target gene promoters, and increased the levels of p21, p27 and CCAAT/enhancer binding protein α in cultured AML cells. In addition, SP2509 treatment or LSD1 shRNA inhibited the colony growth of AML cells. SP2509 also induced morphological features of differentiation in the cultured and primary AML blasts. SP2509 induced more apoptosis of AML cells expressing mutant NPM1 than mixed-lineage leukemia fusion oncoproteins. Treatment with SP2509 alone significantly improved the survival of immune-depleted mice following tail-vein infusion and engraftment of cultured or primary human AML cells. Co-treatment with pan-HDAC inhibitor (HDI) panobinostat (PS) and SP2509 was synergistically lethal against cultured and primary AML blasts. Compared with each agent alone, co-treatment with SP2509 and PS significantly improved the survival of the mice engrafted with the human AML cells, without exhibiting any toxicity. Collectively, these findings show that the combination of LSD1 antagonist and pan-HDI is a promising therapy warranting further testing against AML.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These findings support and provide a molecular explanation for recent observations that combination therapies of KDM1A antagonist and HDAC inhibitors exhibit an enhanced response29.”
From Efficient combinatorial targeting of RNA transcripts in single cells with Cas13 RNA Perturb-seq (2023) · cites this paper as [29]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
The origin and evolution of mutations in acute myeloid leukemia
Welch, J. S., Ley, T. J., Link, D. C., Miller, C. A., Larson, D. E., Koboldt, D. C., Wartman, L. D., Lamprecht, T. L., Liu, F., Xia, J., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.023 · Cited by 1,575
Epigenetic protein families: a new frontier for drug discovery
Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., & Schapira, M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3674 · Cited by 1,327
Interplay between the Cancer Genome and Epigenome
Shen, H., & Laird, P. W. (2013) · Cell · doi:10.1016/j.cell.2013.03.008 · Cited by 949
Molecular mechanisms and potential functions of histone demethylases
Kooistra, S. M., & Helin, K. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3327 · Cited by 913
Regulation of LSD1 Histone Demethylase Activity by Its Associated Factors
Shi, Y.-J., Matson, C., Lan, F., Iwase, S., Baba, T., & Shi, Y. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.08.027 · Cited by 906
The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation
Wang, J., Hevi, S., Kurash, J. K., Lei, H., Gay, F., Bajko, J., Su, H., Sun, W., Chang, H., Xu, G., et al. (2008) · Nature Genetics · doi:10.1038/ng.268 · Cited by 827
p53 is regulated by the lysine demethylase LSD1
Huang, J. L., Sengupta, R., Espejo, A. B., Lee, M. G., Dorsey, J. A., Richter, M., Opravil, S., Shiekhattar, R., Bedford, M. T., Jenuwein, T., et al. (2007) · Nature · doi:10.1038/nature06092 · Cited by 820
Schenk, T., Chen, W. C., Göllner, S., Howell, L., Jin, L., Hebestreit, K., Klein, H.-U., Popescu, A. C., Burnett, A., Mills, K., et al. (2012) · Nature Medicine · doi:10.1038/nm.2661 · Cited by 672
Enhancer decommissioning by LSD1 during embryonic stem cell differentiation
Whyte, W. A., Bilodeau, S., Orlando, D. A., Hoke, H. A., Frampton, G. M., Foster, C. T., Cowley, S. M., & Young, R. A. (2012) · Nature · doi:10.1038/nature10805 · Cited by 602
The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells
Harris, W. J., Huang, X., Lynch, J. T., Spencer, G. J., Hitchin, J. R., Li, Y., Ciceri, F., Blaser, J. G., Greystoke, B. F., Jordan, A. M., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.014 · Cited by 566
Schulte, J. H., Lim, S., Schramm, A. R., Friedrichs, N., Köster, J., Versteeg, R., Øra, I., Pajtler, K. W., Klein‐Hitpaß, L., Kuhfittig-Kulle, S., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1735 · Cited by 447
Fiskus, W. C., Wang, Y., Sreekumar, A., Buckley, K. M., Shi, H., Jillella, A., Üstün, C., Rao, R., Fernandez, P., Chen, J., et al. (2009) · Blood · doi:10.1182/blood-2009-03-213496 · Cited by 372
Self-citationLSD1 regulates the balance between self-renewal and differentiation in human embryonic stem cells
Adamo, A., Sesé, B., Boué, S., Castaño, J., Paramonov, I., Barrero, M. J., & Belmonte, J. C. I. (2011) · Nature Cell Biology · doi:10.1038/ncb2246 · Cited by 348
Yang, M., Gocke, C. B., Luo, X., Borek, D., Tomchick, D. R., Machius, M., Otwinowski, Z., & Yu, H. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.07.012 · Cited by 339
George, P., Bali, P., Annavarapu, S., Scuto, A., Fiskus, W. C., Guo, F., Sigua, C. A., Sondarva, G. V., Moscinski, L. C., Atadja, P. W., et al. (2004) · Blood · doi:10.1182/blood-2004-09-3413 · Cited by 332
Self-citationOver-Expression of LSD1 Promotes Proliferation, Migration and Invasion in Non-Small Cell Lung Cancer
Lv, T., Yuan, D., Miao, X., Lv, Y., Zhan, P., Shen, X., & Song, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035065 · Cited by 279
Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia
Abdel-Wahab, O. I., & Levine, R. L. (2013) · Blood · doi:10.1182/blood-2013-01-451781 · Cited by 261
Wang, J., Lu, F., Ren, Q., Sun, H., Xu, Z., Lan, R., Liu, Y., Ward, D. C., Quan, J., Ye, T., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0896 · Cited by 236
Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice
Vassiliou, G. S., Cooper, J. L., Rad, R., Li, J., Rice, S. V., Uren, A. G., Rad, L., Ellis, P., Andrews, R., Banerjee, R., et al. (2011) · Nature Genetics · doi:10.1038/ng.796 · Cited by 234
A SIRT1-LSD1 Corepressor Complex Regulates Notch Target Gene Expression and Development
Mulligan, P., Yang, F., Stefano, L. D., Ji, J., Ouyang, J., Nishikawa, J. L., Toiber, D., Kulkarni, M., Wang, Q., Najafi-Shoushtari, S. H., et al. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.04.020 · Cited by 221
The histone LSD1 demethylase in stemness and cancer transcription programs
Amente, S., Lania, L., & Majello, B. (2013) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2013.05.002 · Cited by 207
Structural insights into histone lysine demethylation
Hou, H., & Yu, H. (2010) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2010.09.006 · Cited by 179
LSD1-mediated demethylation of histone H3 lysine 4 triggers Myc-induced transcription
Amente, S., Bertoni, A., Morano, A., Lania, L., Avvedimento, E. V., & Majello, B. (2010) · Oncogene · doi:10.1038/onc.2010.120 · Cited by 177
Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma
Sankar, S., Bell, R. N., Stephens, B. J., Zhuo, R., Sharma, S., Bearss, D. J., & Lessnick, S. L. (2012) · Oncogene · doi:10.1038/onc.2012.525 · Cited by 176
Self-citationAgliano, A., Martin‐Padura, I., Mancuso, P., Marighetti, P., Rabascio, C., Pruneri, G., Shultz, L. D., & Bertolini, F. (2008) · International Journal of Cancer · doi:10.1002/ijc.23772 · Cited by 163
Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors
Singh, M. M., Manton, C. A., Bhat, K., Tsai, W.-W., Aldape, K., Barton, M. C., & Chandra, J. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor049 · Cited by 151
LSD1 and the chemistry of histone demethylation
Culhane, J. C., & Cole, P. A. (2007) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2007.07.014 · Cited by 143
DeAngelo, D. J., Spencer, A. G., Bhalla, K. N., Prince, H. M., Fischer, T., Kindler, T., Giles, F. J., Scott, J. W., Parker, K., Liu, A., et al. (2013) · Leukemia · doi:10.1038/leu.2013.38 · Cited by 140
Self-citationErratum: Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma
Sankar, S., Bell, R. N., Stephens, B. J., Zhuo, R., Sharma, S., Bearss, D. J., & Lessnick, S. L. (2016) · Oncogene · doi:10.1038/onc.2016.142 · Cited by 139
Self-citationA Highly Specific Mechanism of Histone H3-K4 Recognition by Histone Demethylase LSD1
Forneris, F., Binda, C., Dall'Aglio, A., Fraaije, M. W., Battaglioli, E., & Mattevi, A. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m607411200 · Cited by 135
Huang, Y., Vasilatos, S. N., Boric, L., Shaw, P. G., & Davidson, N. E. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1480-8 · Cited by 132
Balusu, R., Fiskus, W. C., Rao, R., Chong, D. G., Nalluri, S., Mudunuru, U., Ma, H., Chen, L., Venkannagari, S., Ha, K., et al. (2011) · Blood · doi:10.1182/blood-2010-09-309674 · Cited by 131
Self-citationA robust xenotransplantation model for acute myeloid leukemia
Sanchez, P. V., Perry, R. L., Sarry, J., Perl, A. E., Murphy, K. M., Swider, C. R., Bagg, A., Choi, J. K., Biegel, J. A., Danet-Desnoyers, G. A., et al. (2009) · Leukemia · doi:10.1038/leu.2009.143 · Cited by 127
Matthews, G. M., Newbold, A., & Johnstone, R. W. (2012) · Advances in cancer research · doi:10.1016/b978-0-12-394387-3.00005-7 · Cited by 120
LSD1-mediated epigenetic modification is required for TAL1 function and hematopoiesis
Hu, X., Li, X., Valverde, K., Fu, X., Noguchi, C. T., Qiu, Y., & Huang, S. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900437106 · Cited by 120
Huang, P.-H., Chen, C.-H., Chou, C.-C., Sargeant, A. M., Kulp, S. K., Teng, C., Byrd, J. C., & Chen, C. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.067702 · Cited by 110
Fiskus, W. C., Verstovšek, S., Manshouri, T., Smith, J. E., Peth, K., Abhyankar, S., McGuirk, J. P., & Bhalla, K. N. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0862 · Cited by 109
Self-citationZhao, Z.-K. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i45.6651 · Cited by 85
DeAngelo, D. J., Mesa, R. A., Fiskus, W. C., Tefferi, A., Paley, C. S., Wadleigh, M., Ritchie, E. K., Snyder, D., Begna, K. H., Ganguly, S., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12384 · Cited by 74
Self-citationLi, Y., Deng, C., Hu, X., Patel, B., Fu, X., Qiu, Y., Brand, M., Zhao, K., & Huang, S. (2012) · Oncogene · doi:10.1038/onc.2012.8 · Cited by 67
Lynch, J. T., Cockerill, M. J., Hitchin, J. R., Wiseman, D. H., & Somervaille, T. C. P. (2013) · Analytical Biochemistry · doi:10.1016/j.ab.2013.07.032 · Cited by 59
Targeting p27Kip1protein: its relevance in the therapy of human cancer
Borriello, A., Bencivenga, D., Criscuolo, M., Caldarelli, I., Cucciolla, V., Tramontano, A., Borgia, A., Spina, A., Oliva, A., Naviglio, S., et al. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.561318 · Cited by 56
Superior Efficacy of a Combined Epigenetic Therapy against Human Mantle Cell Lymphoma Cells
Fiskus, W. C., Rao, R., Balusu, R., Ganguly, S., Tao, J., Sotomayor, E. M., Mudunuru, U., Smith, J. E., Hembruff, S. L., Atadja, P. W., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0873 · Cited by 49
Self-citationNovel treatments in acute myeloid leukemia.
Ravandi, F. (2011) · PubMed · Cited by 1
Flagged first, then by citations
Cited by
Sorted by citations
Epigenetic Determinants of CancerPreprint
Baylin, S. B., & Jones, P. A. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a019505 · Cited by 1,414
HDACs and HDAC Inhibitors in Cancer Development and TherapyPreprint
Li, Y., & Seto, E. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026831 · Cited by 1,337
Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials
Cheng, Y., He, C., Wang, M., Ma, X., Mo, F., Yang, S., Han, J., & Wei, X. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0095-0 · Cited by 1,097
LSD1/KDM1A inhibitors in clinical trials: advances and prospects
Fang, Y., Liao, G., & Yu, B. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0811-9 · Cited by 453
Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy
Morera, L., Lübbert, M., & Jung, M. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0223-4 · Cited by 412
Metadata
- Authors
- Fiskus, W., Sharma, S., Shah, B., Portier, B. P., Devaraj, S. G. T., Liu, K., Iyer, S. P., Bearss, D., & Bhalla, K. N.
- Affiliations
- Houston Methodist (US)
- University of Utah (US)
- Brigham Young University (US)
- Corresponding author
- Bhalla, K N
- Venue
- Leukemia
- Published
- 2014-04-04
- Volume
- 28
- Issue
- 11
- Pages
- 2155-2164
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- PMC
- PMC4739780
- OpenAlex
- W2006229882
- Cited by
- 284
- References
- 45
- Citations by year
- 2026: 8 · 2025: 14 · 2024: 21 · 2023: 18 · 2022: 20 · 2021: 18 · 2020: 25 · 2019: 27 · 2018: 26 · 2017: 45 · 2016: 35 · 2015: 21 · 2014: 5
- FWCI
- 25.06
- Type
- journal article
- Language
- en
- Update notices
- erratum (2017-03-21)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Leukemia (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA171338, R01CA173877, R01CA123207)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Keywords
- LSD1, acute myeloid leukemia, histone deacetylase inhibitors, panobinostat, combination therapy, H3K4 demethylation, leukemia cell differentiation, apoptosis, NPM1 mutation, MLL fusion, synergistic lethality
- MeSH terms
- Nucleophosmin, Animals, Cells, Cultured, Disease Models, Animal, Enzyme Inhibitors, Female, Histones, Humans, Hydrazines, Nerve Tissue Proteins, Stem Cells, Sulfonamides, Tumor Cells, Cultured, Leukemia, Myeloid, Acute, Mice, SCID, Mice, Inbred NOD, Apoptosis, Xenograft Model Antitumor Assays, RNA, Small Interfering, Histone Acetyltransferases, Histone Demethylases, Co-Repressor Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
